-  Prevention of venous thromboembolism, particularly in patients undergoing orthopedic surgery, general and oncological surgery, -  Prevention of venous thromboembolism in patients immobilized due to acute conditions, including acute heart failure, acute respiratory failure, severe infections, and exacerbation of rheumatic diseases resulting in immobilization (40 mg/0.4 ml). treatment of deep vein thrombosis complicated by or without pulmonary embolism, -  treatment of unstable angina and Q-wave myocardial infarction, in combination with acetylsalicylic acid (ASA), -  treatment of acute myocardial infarction with ST segment elevation, including patients who will be treated conservatively or who will subsequently undergo percutaneous coronary intervention.(for a dose of 60 mg/0.6 ml, 80 mg/0.8 ml, 100 mg/1 ml) -  prevention of the formation of blood clots in the extracorporeal circulation during hemodialysis.